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Synchronous two distinct neuroendocrine lung cancer lesions
Dwa synchroniczne neuroendokrynne nowotwory płuca
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Abstract
The synchronous primary lung tumors is a rare condition and presented patient is the first reported case of simultaneous two 
distinct neuroendocrine lung cancer lesions in the same lobe. We present the case of a 55-year-old woman with synchronous 
two distinct neuroendocrine lung cancer lesions in the right upper lobe. Initially she showed no signs or symptoms related to lung 
lesions and was admitted to Thoracic Surgery Ward for the investigation of two oval, solitary pulmonary nodules (11 and 19 mm 
in diameter) detected on a chest X-ray performed three months earlier. The radiological imaging showed a variability of growth 
of both lesions (smaller tumor has enlarged while the larger one remained unchanged). After the CT-guided lung biopsy, patient 
underwent right upper lobectomy. Histological examination revealed a small cell carcinoma in one of the tumors and a large cell 
neuroendocrine carcinoma in the other one. The patient was discharged in good condition and lung inflation in chest X-ray and 
qualified for adjuvant chemotherapy with a combination of cisplatin and etoposide and the prophylactic cranial irradiation. Very 
important issues, having impact on outcome of patients with multiple lung tumours is differentiation whether the lesions are 
metastases or synchronous primary lung tumors and the optimal management of these patients.
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Streszczenie
Synchroniczne nowotwory płuc są rzadką chorobą, a prezentowany przypadek to pierwszy opublikowany opis jednoczesnego 
wystąpienia dwóch pierwotnych neuroendokrynnych raków płuca zlokalizowanych w jednym płacie. Przedstawiono przypadek 
55-letniej pacjentki z dwoma pierwotnymi, odrębnymi neuroendokrynnymi rakami płata górnego płuca prawego. Pacjentka została 
przyjęta na oddział chirurgii klatki piersiowej w celu diagnostyki dwóch cieni okrągłych płuca prawego (o średnicy 11 i 19 mm) 
uwidocznionych na zdjęciu RTG klatki piersiowej wykonanym trzy miesiące wcześniej. Przy przyjęciu pacjentka nie prezentowała 
żadnych objawów związanych ze zmianami w płucu. Dalsze badania obrazowe wykazały zmienność wzrostu obu zmian (mniejszy 
guz uległ powiększeniu, natomiast średnica większego pozostała bez zmian). Po dalszej diagnostyce obejmującej biopsję płuca 
pod kontrolą tomografii komputerowej, pacjentkę poddano operacji usunięcia płata górnego płuca prawego. Wynik badania 
histopatologicznego usuniętej tkanki płucnej wykazał, że jeden z guzów jest rakiem drobnokomórkowym, drugi natomiast wielko-
komórkowym rakiem neuroendokrynnym. Po kontrolnym zdjęciu RTG klatki piersiowej, które wykazało pełne upowietrznienie obu 
płuc, pacjentka została wypisana do domu w stanie ogólnym dobrym. Pacjentkę zakwalifikowano do adjuwantowej chemioterapii 
z zastosowaniem cisplatyny oraz etopozydu, a także do profilaktycznego naświetlania czaszki. Bardzo ważnym zagadnieniem ma-
jącym wpływ na wyniki leczenia pacjentów z mnogimi guzami w płucach jest różnicowanie zmian przerzutowych od nowotworów 
synchronicznych, a także szybkie wdrożenie właściwego leczenia. 
Słowa kluczowe: synchroniczny rak płuca, wielkokomórkowy neuroendokrynny rak płuca, drobnokomórkowy rak płuca
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Figure 1. Chest roentgenograms showing progression of the lesions, taken at (A) three months and (B) one week prior to the surgery
Rycina 1. Zdjęcia retgenowskie obrazujące przyrost zmian, zrobione trzy miesiące (A) i tydzień (B) przed zabiegiem operacyjnym
A B
Introduction
Multiple synchronous primary lung cancers 
are unusual and the incidence is reported around 
0.2−20% [1]. Recently its rise has been noted due 
to widespread use and improvements in comput-
ed tomography (CT), positron emission tomogra-
phy (PET) and other diagnostic methods. Once the 
detection of multiple solitary pulmonary nodules 
has been made, a very important issue, having 
a tremendous impact on treatment, is differentia-
tion whether these lesions are metastases or syn-
chronous primary lung tumors. There are several 
factors included in the criteria given by Martini 
and Melamed for the diagnosis of synchronous 
multiple primary lung tumors, such as histolog-
ical characteristic of the tumors, their location, 
metastasis or vascular invasion occurrence [2]. 
In this article, we present the patient with two 
synchronous neuroendocrine lung cancer lesions 
in the right upper lobe. 
Case report
A 55-year-old woman was admitted to Tho-
racic Surgery Ward for the investigation of two 
oval, solitary pulmonary nodules, 11 and 19 mm 
in diameter detected on a chest X-ray (Fig. 1). 
This was performed three months earlier prior 
to resection of retrosternal goiter, complicated 
by vocal cord paralysis, which necessitated tra-
cheotomy. On admission, the patient showed no 
signs or symptoms related to lung lesions. Total 
tobacco consumption exceeded 32 pack-years. 
Control chest roentgenogram and CT showed 
progression of the lesions — medial tumor has 
enlarged from 11 mm to 23 mm, while the lateral 
one remained unchanged (Fig. 1). Due to the ra-
diological imaging, the patient was qualified for 
CT-guided lung biopsy, which revealed poorly 
differentiated non-small cell carcinomas cells. 
Patient underwent right upper lobectomy. The 
lateral thoracotomy procedure was performed 
under general anaesthesia with single lung ven-
tilation. Lymph node station 7 and 10 were sam-
pled. Histological examination of the resected 
lung tissue revealed medially localized tumor to 
be a small cell carcinoma and the lateral tumor 
to be a large cell neuroendocrine carcinoma 
(Fig. 2). Immunochemical staining of the large 
cell neuroendocrine carcinoma showed positive 
reactions to cytokeratin, chromogranin A and syn-
aptophysin, as well as negative reaction to TTF1; 
Ki67 (proliferation index marker) was 70%. Small 
cell carcinoma was focal positive (“dot like”) 
to cytokeratin, positive to chromogranin A and 
synaptophysin and focal positive to TTF1; Ki67 
was 70%. Histological analysis of taken lymph 
nodes revealed no evidence of cancer cells. The 
post-operative recovery was complicated by per-
sistent parenchymal air leakage, which required 
talc pleurodesis. Chest drains were removed in 
3rd and 6th postoperative day. The patient was 
discharged in good condition and lung inflation 
in chest X-ray. Afterwards the patient was qual-
ified for adjuvant chemotherapy. A combination 
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Figure 2. Histological appearance of lung carcinomas. (A) Small cell carcinoma. (B) Large cell neuroendocrine carcinoma
Rycina 2. Obraz histopatologiczny raków płuca. (A) rak drobnokomókowy; (B) neuroendokrynny rak wielkokomórkowy
of cisplatin and etoposide was given in a three 
series of treatments over a period of three months, 
with a two weeks breaks in between. CT scans of 
chest, brain and abdomen, performed after treat-
ment showed no signs of distant metastasis. The 
last stage of treatment was prophylactic cranial 
irradiation, which patient underwent without 
any complications.
Now, 22 months after surgical treatment, 
being under thorough surveillance, the lady is fit 
and well showing no signs of relapse.
Discussion
The synchronous primary lung tumors are 
a rare condition and despite several reported se-
ries of patients [1−3], or case reports describing 
even three synchronous histologically different 
primary tumors in one lobe [4]. We present the 
first reported case of simultaneous two distinct 
neuroendocrine lung cancer lesions in the same 
lobe.
Large-cell neuroendocrine carcinomas of the 
lung are aggressive tumors. Patients with that kind 
of carcinoma have an extremely poor prognosis 
since the biological behavior is similar to that of 
small cell lung carcinomas [5, 6]. The classifica-
tion of high-grade neuroendocrine lung tumours 
currently recognises large-cell neuroendocrine 
carcinoma and small-cell lung carcinoma as di-
stinct groups [7, 8]. However Jones et al. [9] sug-
gest that a single high-grade neuroendocrine lung 
tumours classification would be more appropriate 
due to a similarity in histology for these two car-
cinomas and uncertain clinical course. The WHO 
lung cancer classification distinguishes combined 
type of small cell carcinoma with elements of 
large cell neuroendocrine carcinoma. However in 
our patient lesions were physically distinct and 
separate and therefore meets the criteria given 
by Martini and Melamed for the diagnosis of 
synchronous multiple primary lung tumors [2]. 
Evident difference in the rate of growth of these 
two types of carcinomas also confirms primary 
nature of each tumors.
Still controversial remains the optimal ma-
nagement of patients with synchronous lung 
tumors. The operative management of these 
patients requires careful analysis at each stage 
of evaluation and the extension of resected lung 
tissue depends on localization of each tumors 
[1, 10]. The treatment for patients with large cell 
neuroendocrine carcinoma has been based on 
non-small cell carcinomas. To improve the result 
of treatment these kind of carcinoma, very impor-
tant issue is to understand its clinicopathological 
characteristics, including preoperative diagno-
ses, the effectiveness of adjuvant chemotherapy, 
tumor recurrence rates and the prognosis of dif-
ferent stages [5, 11, 12]. Kocaturk et al. evaluated 
the benefits resulting from the use of adjuvant 
chemo- or radiotherapy to improve the three year 
survival in comparison with patients not under-
going adjuvant therapy (66.7 vs. 56.3%) [13].
As this is a case report, it is obvious that our 
patient will be treated on the individual basis, 
depending on the pathological characteristics of 
potential recurrence. It is to some extent likely 
that the relapse, if any, will appear as a small cell 
cancer lesion due to higher metastasizing capa-
bility and proliferation rate, compared to large 
cell cancer. In such circumstances the patient 
should be treated with second-line chemotherapy 
supplemented with radiotherapy. However, if the 
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large cell cancer clone will be predominant, then, 
paradoxically, the prognosis may be poorer due to 
chemo- and radiotherapy insesitiveness. 
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